The statistical design of the drug survey included as many as 224 drug molecules belonging to 15 different therapeutic categories of the NLEM 2011
The Ministry of Health and Family Welfare, Government of India had entrusted the work relating to carrying out a survey of the extent of Problems of ‘Spurious and Not of Standard Quality Drugs’ to the National Institute of Biologicals (NIB), Noida. The NIB has since submitted the report to the government.
The statistical design of the drug survey included as many as 224 drug molecules belonging to 15 different therapeutic categories of the National List of Essential Medicines (NLEM) 2011. As part of this survey, 47,954 drug samples relating to 23 dosage forms were drawn from 654 districts of 36 states and Union Territories from the supply chains including retail outlets, government sources and from eight airports and sea ports.
A nationwide training in drugs survey methodology was imparted at 28 centres across the country to over 1800 Sample Drawing Officers (SDOs) and representatives of the Civil Society/ Pharmacy Council of India (PCI). The role of the Civil Society/ Pharmacy Council of India (PCI) representatives was to observe that the drugs samples are drawn in accordance with the sampling methodology and the highest degree of transparency and objectivity is maintained in the process to eliminate any bias.
All the samples were subjected to test/ analysis as per pharmacopoeial requirements in the Central and State Drug Testing Laboratories that have been accredited by NABL. Overall, out of the 47,012 samples tested, 13 samples were found to be Spurious and 1,850 samples were found to be ‘Not of Standard Quality’ (NSQ). As such, the percentage of NSQ Drugs in India has been found to be 3.16 per cent and that of Spurious drugs 0.0245 per cent.